Objectives. Primary inefficacy of TNF inhibitors (TNFi) for axial spondyloarthritis (axSpA) is infrequent. The objective of this study was to assess the long-term evolution and final diagnosis of patients with primary inefficacy of TNFi for axSpA.
Introduction
TNF inhibitors (TNFi) are extremely effective in axial spondyloarthritis (axSpA). Many studies have shown major improvement in SpA activity after TNFi therapy, and currently it is the only drug therapy approved for axSpA patients with insufficient response to NSAIDs [1] . However, some patients are non-responders: primary inefficacy, that is, an initial lack of treatment response appears infrequent in axSpA, with rates of 515% [25] .
The diagnosis of SpA is difficult and is based on a body of clinical arguments associated with laboratory tests and radiological signs [68] ; several of the clinical criteria contributing to the diagnosis of axSpA, such as enthesitis pain, lack specificity [6] . Furthermore, some frequent diseases or conditions such as OA, widespread pain syndrome and depression could interfere either with the activity of SpA (falsely heightened disease activity) or with the response to TNFi (falsely heightened inefficacy) [911] . Thus, considering the rarity of primary inefficacy and the difficulty of diagnosing axSpA, it seemed useful to explore the cases of primary inefficacy to TNFi in axSpA: who are these patients who have primary inefficacy? What are their demographic and disease characteristics and their final diagnosis? Do they have comorbidities? Is a second course of TNFi worth considering for these patients?
The objective of the present study was to describe axSpA patients with primary inefficacy after the first TNFi, 510 years after their prescription, in terms of diagnosis, comorbidities and current management.
Patients and methods

Study design
This was a systematic retrospective and prospective study conducted in one tertiary care centre in Paris, France.
Population
All patients with a diagnosis of axSpA according to an expert rheumatologist, Amor criteria and receiving a first TNFi in the context of usual practice between 2004 and 2009 in the centre were analysed. The available information was retrospectively collected from the medical files [3] . For the present study, the focus was on those patients who had primary inefficacy to this first TNFi. Primary inefficacy was defined here as treatment interruption 34 months after treatment onset, with a rheumatologist assessment in the medical file citing lack of efficacy as primary reason for drug interruption. The rheumatologist's reason for stopping the treatment was based on a mixture of efficacy (assessed by BASDAI) as well as patient preference, in the context of usual practice.
Data collected at baseline
At baseline, demographic and disease (type of disease, presence of extra-articular signs, HLAB27 status, the presence of imaging sign and of elevated acute phase reactants in particular CRP characteristics were collected.
Long-term follow-up (prospective phase)
In 201314, patients with primary inefficacy were contacted by letter and seen in the outpatient clinic if possible for clinical examination and medical interview. If this was not possible, they were contacted by telephone and asked to fill in a questionnaire. If the patients did not answer the letter or the two reminders, their general practitioner was contacted to either ask the patient to participate to the study, or to give us information on the patient's status.
Patients gave their consent for the use of the collected data, and the study was conducted in accordance with the Declaration of Helsinski. Due to the non-interventional nature of the study, ethical approval was not required for the prospective phase of the study.
Data collected at follow-up
Disease characteristics were collected, including the type of disease (axial only, or associated with enthesitic or peripheral arthritis), the presence of extraarticular signs, the HLAB27 status, the presence of imaging signs (sacroiliitis, syndesmophytes on the most recent available imaging) and of elevated acute-phase reactants, in particular CRP. AxSpA disease activity was evaluated through an investigator global visual analogue scale, the BASDAI and the BASFI as well as a full clinical evaluation where possible [12, 13] . ASDAS was not used in 2014 because CRP was not always available. Current treatment was collected, including NSAIDs intake, TNFi and type, and treatment maintenance.
The association with widespread pain syndrome was assessed with the Fibromyalgia Rapid Screening Tool questionnaire; this validated questionnaire comprises six questions and a score of 55/6 is strongly suggestive of widespread pain syndrome [14] . Concomitant spine or lower-limb OA and concomitant or past depression were assessed by the physician (S.K.) during the visit, or by simple questions by phone and/or in the questionnaire. These data were confirmed where possible in the medical file.
The final diagnosis, that is, confirmation of axSpA diagnosis or not, was evaluated both by applying the Assessment of SpondyloArthritis (ASAS) classification criteria for axSpA [12] and through the rheumatologist's opinion, based on the full evaluation (including clinical assessment, imaging and biological results when available).
The fulfilment of the ASAS classification criteria for axSpA was also checked.
Statistical analysis
Descriptive data were summarized using means and S.D. Comparisons were performed by parametric tests. For patients who had received a second TNFi, the survival rate at 1 year was assessed using KaplanMeier survival curves on SAS version 9.2.
Results
SpA patients with primary inefficacy
Of 222 axSpA patients who received a first TNFi between 2004 and 2008, 27 (12%) had interrupted treatment due to primary inefficacy (Table 1 ) [7] . When compared with the 195 patients not classified as having primary inefficacy, these patients were more often female (48 vs 27% in patients without primary inefficacy, P = 0.04), were older at initiation of the TNFi (45 vs 39 years, P = 0.04), had higher BASFI (68 vs 42, P = 0.03) and less frequently had an www.rheumatology.oxfordjournals.org increased CRP (abnormal value according to the laboratory limits: 33 vs 63%, P = 0.02). Among the 27 patients with primary inefficacy, 15 patients (56%) carried the HLA B27 and 18 (67%) had radiographic sacroiliitis. There was no assessment of comorbidities in patients who did not have primary inefficacy.
Long-term follow-up
Among these 27 patients with primary inefficacy, 25 (92%) were re-evaluated after 510 years [mean (SD) follow-up, 6.0 (3.1) years]: 9 with a full clinic exam, 5 through a telephone interview, 5 through a self-reported questionnaire and 6 were re-evaluated only through the medical file. One patient refused to participate in the study and one patient was lost to follow-up. Medical files were used to complement the findings for all patients, and for 5 patients, the private practice physician also gave information. Among the 25 patients who were followed up, 13 (52%) were women, and the mean (S.D.) age at the time of their follow-up was 52.6 (14.6) years (Table 2) . At the longterm follow-up, all the patients still presented symptoms and back pain, although the level of symptoms was moderate: the mean BASDAI was 42 (21).
Concerning their current treatment, 9 (36%) were being treated with TNFi and 9 (36%) were taking NSAIDs. The other patients were being prescribed analgesic drugs and/ or non-pharmacological measures.
Comorbidities
Five (20%) patients had widespread pain syndrome according to the FIRST questionnaire; all were female. Ten (40%) patients had OA of the lower-limb peripheral joints or of the spine; 8 (32%) patients had a selfdeclared diagnosis of depression, and of these 3 (12%) were taking anti-depressant drugs. Overall, 18 (72%) patients had at least one of these three comorbidities.
These patients had the following characteristics: 9 (36%) carried HLA B27, 12 (48%) had radiographic sacroiliitis, 10 (40%) had an increased CRP, 7 (28%) had a family history of SpA and 13 (52%) were considered good responders to NSAIDs. 
TNFi after primary inefficacy
In all, 16 (64% of 25) patients switched to another TNFi: 9 (36%) received two TNFi's and 7 (28%) received 3 or more prescriptions of TNFi. Among the patients who had at least a second TNFi, the treatment was considered efficacious for 9 (56% of 16) patients, whereas 7 presented with primary inefficacy to the second TNFi. The retention rate of the second TNFi at 1 year was 50%. At the time of follow-up, 9 (36%) patients were still prescribed a TNFi. Note that over all patients (those with primary inefficacy and those without), 111 (57%) patients stopped the first TNF inhibitor over the duration of follow-up, with a mean (S.D.) follow-up of 29 months (20.1).
Final diagnosis
In all, 21 (84%) patients satisfied the ASAS classification criteria for axSpA [12] . Furthermore, the diagnosis of axSpA was confirmed according to the rheumatologist's opinion for 20 (80%) patients. Seventeen (68%) patients fulfilled both conditions.
Discussion
This study confirms the infrequent nature of primary inefficacy of TNFi in axSpA (12%) and shows that most of the patients with primary inefficacy to their first TNFi had confirmed axSpA, but also that most of them had comorbidities that could affect axSpA evaluation. This is important because practitioners might consider that primary inefficacy to TNFi leads to reconsidering the diagnosis of SpA (i.e. the notion of a TNFi prescription being used as the diagnostic test). We suggest here that primary inefficacy should not be considered as equivalent to a diagnostic error, and that a second prescription of TNFi may be of use in such patients, although painful comorbidities should certainly be screened for and taken into account.
This study has strengths and weaknesses. We performed a systematic assessment of all patients receiving a TNFi in a single centre over a defined period of time, allowing a true assessment of the frequency of primary inefficacy. We also managed to reassess almost all of the patients with initial primary inefficacy, with a longterm follow-up (mean, 6 years) that allowed true reconsideration of the evolution and diagnosis of the patients. Wherever possible, patients were assessed fully through clinical examination, history-taking and imaging at followup. No such data was available at baseline; in particular there was no assessment of comorbidities. However, the number of patients assessed was low, due to the relative rarity of primary inefficacy. Not all patients accepted the invitation to come into the clinic for a full physical assessment; in fact, for six patients we could only use the hospital medical file (which is a limitation to the systematic character of the study). Finally, the definition used here for primary inefficacy, that is, an interruption of the TNFi therapy in the 34 months following its introduction, with the physician putting primary inefficacy as the reason can be discussed. Indeed, 3 months may be a little too short to properly assess the efficacy of TNFi; and a quantitative assessment such as the BASDAI would have been more optimal [15] . However, this is a clinical-practice, real-life assessment, and we believe that the patients who did interrupt their treatment at 3 months were indeed in a situation of primary inefficacy.
This study showed that patients with axSpA who had primary inefficacy had slightly different clinical characteristics from those with primary efficacy-above all, much comorbidity, such as widespread pain syndrome, depression or OA. Widespread pain syndrome is not rare in SpA, and in particular in the absence of radiological signs of SpA, it raises the question of non-radiographic forms of axSpA [16] . The present study does not give new data regarding non-radiographic axSpA, but it does confirm that widespread pain syndrome should be considered when physicians are faced with primary inefficacy in axSpA. The FIRST questionnaire used in the present study is a user-friendly questionnaire for clinical practice, and it may be of use for the diagnosis of widespread pain syndrome if its performances are confirmed [14] .
If an association between SpA and depressive syndrome is known [17] , this study reveals that depression could explain therapeutic failures in axSpA, and it may support the concept of systematically screening for depression. However, simple-to-use tools to diagnose depression in the setting of a rheumatology clinic are currently lacking (A. Baillet, unpublished results).
The present results suggest the importance of a global approach for managing these patients. Widespread pain syndrome, OA and depression are very common comorbidities and should systematically be screened and treated, for better therapeutic management. It would be interesting to do other studies to compare the link between comorbidities and response to TNFi.
The present study indicated a switch to a second TNFi may be worthwhile for patients who show lack of response to a first TNFi. Indeed, in the present study, 16 patients received a second TNFi and importantly, the treatment was considered effective in 9 (56%) patients. Although previous studies had indicated the efficacy of TNFi switches in axSpA, this is the first study to specifically look at patients with primary inefficacy to a first TNFi [25] .
The fact that patients who demonstrated primary inefficacy to their first TNFi often have a confirmed diagnosis of axSpA confirms that the TNF pathway is not the only pathway involved in these pathologies [18] , explaining why some patients do not respond to TNFi therapy. Data regarding the efficacy of new therapeutics developed against the IL17/IL23 pathway in these patients, would be of interest [18] .
In conclusion, SpA, like other chronic inflammatory diseases, requires a holistic approach with appropriate assessment and management of potential comorbidities. Primary inefficacy of a first TNFi should not bar a second TNFi prescription but a careful assessment of potentially painful comorbid conditions would be useful in such a situation.
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